Silexion Therapeutics Corp Warrant
SLXNW$0.03 +0.01 (39.04%)
Company News
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices regarding its planned Phase 2/3 clinical trial for SIL204, a potential treatment for locally advanced pancreatic cancer. The guidance provides regulatory clarity and supports the company's planned trial initiation in Q2 ...
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
U.S. stock futures were mixed ahead of the Federal Reserve's interest rate decision and key earnings reports from major tech companies. Investors are cautious as they await the Fed's policy announcement and guidance.
